

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listing of claims in the application.

Listing of claims

1-86. (Cancel)

87. (Currently Amended) ~~The~~ An isolated polypeptide capable of specific binding to factor VIII and comprising a heavy chain variable region of a human antibody with factor VIII specificity and a light chain variable region of a human antibody, wherein the heavy chain variable region comprises a sequence selected from the group consisting of SEQ. ID. NO: 23, SEQ. ID. NO: 24, SEQ. ID. NO: 25, SEQ. ID. NO: 26, SEQ. ID. NO: 27, SEQ. ID. NO: 28, SEQ. ID. NO: 31, SEQ. ID. NO: 32, SEQ. ID. NO: 33, SEQ. ID. NO: 34, SEQ. ID. NO: 35, SEQ. ID. NO: 36, SEQ. ID. NO: 37, SEQ. ID. NO: 38, SEQ. ID. NO: 51, SEQ. ID. NO: 52, and SEQ. ID. NO: 53 ~~according to claim 17, SEQ. ID. NO: 24, 26, 31, 33, 35, 37, or 52.~~

88. (New) The isolated polypeptide of claim 87, which is capable of interfering with the activity of factor VIII inhibitors, and wherein the heavy chain variable region comprises a sequence selected from the group consisting of SEQ ID NO: 24 and SEQ ID NO: 26.

89. (New) The isolated polypeptide of claim 87, which is capable of interfering with the activity of factor VIII inhibitors, and wherein the heavy chain variable region comprises a sequence selected from the group consisting of SEQ. ID. NO: 25, SEQ. ID. NO: 23, SEQ. ID. NO: 27, and SEQ. ID. NO: 28.

90. (New) The isolated polypeptide of claim 87, wherein the heavy chain variable region comprises a sequence selected from the group consisting of SEQ. ID. NO: 32,

SEQ. ID. NO: 34, SEQ. ID. NO: 36, SEQ. ID. NO: 38, SEQ. ID. NO: 51 and SEQ. ID. NO: 53.

91. (New) The isolated polypeptide of claim 87, wherein said polypeptide is a single chain Fv fragment.

92. (New) The isolated polypeptide of claim 87, wherein said polypeptide is an antibody.

93. (New) The isolated polypeptide of claim 92, wherein said antibody is an IgG.

94. (New) The isolated polypeptide of claim 87, wherein said polypeptide specifically binds the heavy chain of factor VIII.

95. (New) The isolated polypeptide of claim 87, wherein said polypeptide specifically binds a domain of the heavy chain of factor VIII consisting of the A1 domain, the A2 domain and the B domain of factor VIII.

96. (New) The isolated polypeptide of claim 87, wherein said polypeptide specifically binds the light chain of factor VIII.

97. (New) The isolated polypeptide of claim 87, wherein said polypeptide specifically binds a region of the light chain of factor VIII consisting of the A3 domain, the C1 domain and the C2 domain of factor VIII.

98. (New) A pharmaceutical composition for the treatment of factor VIII inhibition in a human individual, comprising the isolated polypeptide according to claim 87 together with a pharmaceutically acceptable carrier.

99. (New) A pharmaceutical composition for the treatment of factor VIII inhibition in a human individual, comprising the isolated polypeptide according to claim 88 together with a pharmaceutically acceptable carrier.

100. (New) A pharmaceutical composition for the treatment of factor VIII inhibition in a human individual, comprising the isolated polypeptide according to claim 89 together with a pharmaceutically acceptable carrier.